- Sepsis Awareness: Advancing Timely Diagnosis
- Supporting Ebola Response: Rapid Diagnostics and Global Expertise
- Progress Toward a More Sustainable Future
News
For patients at risk of sepsis, time matters. Faster diagnostic information can help healthcare teams identify the cause of infection sooner, supporting earlier better-informed care decisions.
Swipe for more stories
-
First-Half 2026 Results
bioMérieux's Q2 2026 sales totaled €981 million, with solid organic growth at +5%, reaching +7% excluding BIOFIRE® respiratory panels. The sales of the GO•28 growth drivers increased by 8.5% organically in Q2 26. -
bioMérieux Launches PCR Testing Solution to Verify Probiotic Species in Dietary Supplements Manufacturing
With GENE-UP® PROBIOTIC SPECIES ID, bioMérieux introduces a first-of-its-kind commercialized species-level identification PCR solution for in-house quality control teams and external laboratory partners. -
bioMérieux submits 510(k) to U.S. FDA for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens
bioMérieux, a world leader in the field of in vitro diagnostics, today announces the submission of the BIOFIRE® FILMARRAY® Gastrointestinal 1.1 (GI1.1) Panel and the BIOFIRE® FILMARRAY® Gastrointestinal 1.1 (GI1.1) Panel Mid to the U.S. Food and Drug Administration (FDA) for 510(k) review. These PCR* molecular panels test 22 and 11, respectively, of the most common bacteria, viruses, and parasites associated with gastroenteritis, all from one sample, with results available in approximately one hour.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19